- Home
- GNPX vs SLXN Comparison
GNPX vs SLXN Comparison
Compare GNPX & SLXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNPX
- SLXN
- Stock Information
- Founded
- GNPX 2009
- SLXN 2008
- Country
- GNPX United States
- SLXN Israel
- Employees
- GNPX N/A
- SLXN N/A
- Industry
- GNPX Biotechnology: Pharmaceutical Preparations
- SLXN
- Sector
- GNPX Health Care
- SLXN
- Exchange
- GNPX Nasdaq
- SLXN NYSE
- Market Cap
- GNPX 6.1M
- SLXN 5.2M
- IPO Year
- GNPX 2018
- SLXN N/A
- Fundamental
- Price
- GNPX $0.75
- SLXN $0.74
- Analyst Decision
- GNPX Strong Buy
- SLXN Strong Buy
- Analyst Count
- GNPX 1
- SLXN 1
- Target Price
- GNPX $10.00
- SLXN $9.00
- AVG Volume (30 Days)
- GNPX 367.1K
- SLXN 1.4M
- Earning Date
- GNPX 11-13-2024
- SLXN 02-21-2025
- Dividend Yield
- GNPX N/A
- SLXN N/A
- EPS Growth
- GNPX N/A
- SLXN N/A
- EPS
- GNPX N/A
- SLXN N/A
- Revenue
- GNPX N/A
- SLXN N/A
- Revenue This Year
- GNPX N/A
- SLXN N/A
- Revenue Next Year
- GNPX N/A
- SLXN N/A
- P/E Ratio
- GNPX N/A
- SLXN N/A
- Revenue Growth
- GNPX N/A
- SLXN N/A
- 52 Week Low
- GNPX $0.28
- SLXN $0.21
- 52 Week High
- GNPX $13.00
- SLXN $13.56
- Technical
- Relative Strength Index (RSI)
- GNPX 40.74
- SLXN N/A
- Support Level
- GNPX $0.66
- SLXN N/A
- Resistance Level
- GNPX $0.74
- SLXN N/A
- Average True Range (ATR)
- GNPX 0.06
- SLXN 0.00
- MACD
- GNPX 0.00
- SLXN 0.00
- Stochastic Oscillator
- GNPX 35.04
- SLXN 0.00
About GNPX Genprex Inc.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.
About SLXN BIOMOTION SCIENCES
Silexion Therapeutics Corp is a developmental-stage company dedicated to the development of treatments for pancreatic cancer. The company is focused on enhancing its first-generation product (LODERTM ) to develop a newly formulated product to improve the clinical efficacy against pancreatic cancer.